EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians

Irene Marco, Juan Carlos López-Azor García, Javier González Martín, Andrea Severo Sánchez iD, María Dolores García-Cosío Carmena, Esther Mancebo Sierra iD, Javier de Juan Bagudá, Javier Castrodeza Calvo, Francisco José Hernández Pérez, Juan Francisco Delgado iD

Journal of Clinical Medicine · 02.12.2023 · 12 (23) · 7474

DOI: 10.3390/jcm12237474 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.12.2023. Verfasst von Irene Marco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario La Paz, 28046 Madrid, Spain. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies directed against donor-specific human leukocyte antigens (HLAs) can be detected de novo after heart transplantation and play a key role in long-term survival. De novo donor-specific antibodies (dnDSAs) have been associated with cardiac allograft vasculopathy, antibody-mediated rejection, and mortality. Advances in detection methods and international guideline recommendations have encouraged the adoption of screening protocols among heart transplant units. However, there is still a lack of consensus about the correct course of action after dnDSA detection. Treatment is usually started when antibody-mediated rejection is present; however, some dnDSAs appear years before graft failure is detected, and at this point, damage may be irreversible. In particular, class II, anti-HLA-DQ, complement binding, and persistent dnDSAs have been associated with worse outcomes. Growing evidence points towards a more aggressive management of dnDSA. For that purpose, better diagnostic tools are needed in order to identify subclinical graft injury. Cardiac magnetic resonance, strain techniques, or coronary physiology parameters could provide valuable information to identify patients at risk. Treatment of dnDSA usually involves plasmapheresis, intravenous immunoglobulin, immunoadsorption, and ritxumab, but the benefit of these therapies is still controversial. Future efforts should focus on establishing effective treatment protocols in order to improve long-term survival of heart transplant recipients.

Schlagwörter

Stichwörter der Autor:innen

antibody-mediated rejectiondonor-specific antibodyheart transplantationimmunosuppressionlate graft dysfunction

Autor:innen und Institutionen

  • Cardiology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Cardiology Department, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
  • Centro Nacional de Investigaciones Biomédicas en Red de Enfermedades CardioVasculares (CIBERCV), 28029 Madrid, Spain.
  • School of Medicine, Universidad Europea de Madrid, 28670 Madrid, Spain.
  • Cardiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Immunology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.

ORCID-Profile: Andrea Severo Sánchez, Esther Mancebo Sierra, Juan Francisco Delgado

Zitieren

APA

Marco, I., López-Azor García, J. C., González Martín, J., Severo Sánchez, A., García-Cosío Carmena, M. D., Mancebo Sierra, E., de Juan Bagudá, J., Castrodeza Calvo, J., Hernández Pérez, F. J., & Delgado, J. F. (2023). De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians. Journal of Clinical Medicine, 12(23), 7474. https://doi.org/10.3390/jcm12237474

Vancouver

Marco I, López-Azor García JC, González Martín J, Severo Sánchez A, García-Cosío Carmena MD, Mancebo Sierra E, et al. De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians. Journal of Clinical Medicine. 2023;12(23):7474. doi:10.3390/jcm12237474

BibTeX
@article{Marco2023,
  author = {Marco, Irene and López-Azor García, Juan Carlos and González Martín, Javier and Severo Sánchez, Andrea and García-Cosío Carmena, María Dolores and Mancebo Sierra, Esther and de Juan Bagudá, Javier and Castrodeza Calvo, Javier and Hernández Pérez, Francisco José and Delgado, Juan Francisco},
  title = {De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {23},
  pages = {7474},
  doi = {10.3390/jcm12237474}
}
Kostenlos starten →